Precision at the electrode: a decade of directional neurostimulation, validated in humans
Precision at the electrode: a decade of directional neurostimulation, validated in humans
Aleva built a MEMS-based directional neuromodulation platform from the ground up, from electrode design to human clinical data. The technology is now available to partners through structured licensing and tech transfer
Aleva built a MEMS-based directional neuromodulation platform from the ground up, from electrode design to human clinical data. The technology is now available to partners through structured licensing and tech transfer
The Differentiation Is in the Lead
The Differentiation Is in the Lead
Aleva’s MEMS-based directional lead combines 12 fully independent contacts, rounded electrode geometry and lower imaging artefacts to support precise field shaping and electrode-level control. As part of the directSTIM system, the platform can be licensed by component, module or full system.
Aleva’s MEMS-based directional lead combines 12 fully independent contacts, rounded electrode geometry and lower imaging artefacts to support precise field shaping and electrode-level control. As part of the directSTIM system, the platform can be licensed by component, module or full system.
Validated in Humans
Validated in Humans
Aleva’s directional neuromodulation platform is supported by human clinical data and published directional stimulation research. The evidence points to symptom improvement, medication reduction and a wider therapeutic window for directional stimulation.
Aleva’s directional neuromodulation platform is supported by human clinical data and published directional stimulation research. The evidence points to symptom improvement, medication reduction and a wider therapeutic window for directional stimulation.
48% Symptom Improvement
With stimulation on,
medication off - PMCF
63% Medication Reduction
At 6 months, post-market
follow-up - PMCF
41.3% Wider Therapeutic Window
Directional vs omnidirectional
Brain, Oxford Academic, 2014
100 Granted
Patents
Across 10+ patent families,
protected IP portfolio
A Platform Built for Licensing and Partnerships
A Platform Built for Licensing and Partnerships
Aleva’s MEMS-based directional neuromodulation platform can be licensed by patent family, component, module or full system. Partners can start with a defined indication or interface, then expand scope over time with access to platform knowledge, manufacturing know-how and EPFL-rooted technical expertise.
Aleva’s MEMS-based directional neuromodulation platform can be licensed by patent family, component, module or full system. Partners can start with a defined indication or interface, then expand scope over time with access to platform knowledge, manufacturing know-how and EPFL-rooted technical expertise.
Redefining the future of
precision neuromodulation
Redefining the future of
precision neuromodulation
Born at EPFL Lausanne, Aleva unites medical expertise and microengineering excellence to advance the next generation of directional brain stimulation.
Born at EPFL Lausanne, Aleva unites medical expertise and microengineering excellence to advance the next generation of directional brain stimulation.
Proven Technology
& Clinical Evidence
Aleva developed the world’s first truly directional Deep Brain Stimulation system, CE-marked, clinically validated, and now expanding into new indications such as epilepsy, OCD, and essential tremor. Backed by 120+ patents and proprietary MEMS thin-film electrodes, it delivers superior precision and a five-year lead over conventional DBS systems.
Designed for
Clinical Precision
Aleva’s directional DBS platform was engineered with the clinician in mind — offering intuitive programming, faster surgical setup, and reduced post-operative adjustments. Directional control enables precise targeting with fewer side effects, improving both patient outcomes and workflow efficiency.
Market Positioning
& Investment Signals
The global DBS market is projected to triple by 2030; Aleva is positioned to expand through licensing and new neurological indications.
Interested in Aleva’s platform or partnership opportunities?
Interested in Aleva’s platform or partnership opportunities?
Interested in Aleva’s platform or partnership opportunities?
Tracing the Path Toward Redefining Neurological Treatment Through Directional Brain Stimulation
Founded in 2008, Aleva Neurotherapeutics is a Swiss-engineered, CE-marked company backed by long-term clinical data and over 120 patents.
Tracing the Path Toward Redefining Neurological Treatment Through Directional Brain Stimulation
Founded in 2008, Aleva Neurotherapeutics is a Swiss-engineered, CE-marked company backed by long-term clinical data and over 120 patents.